ArticleActa neuropathologica2023

Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification.

Jack Goddard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.